United States: Complicated Landscape Awaits New FDA Commissioner

Ethan-Jorgensen-Earp is a Public Affairs Advisor in our Washington D.C. office.


  • Dr. Scott Gottlieb's confirmation as Commissioner of Food and Drugs marks an opportunity for Congress and the public to determine whether he will be able to break the status quo at the U.S. Food and Drug Administration (FDA) or merely uphold it.
  • Several near-term issues will affect FDA operations, staffing and other resources, potentially putting the agency chief in the position of having to educate – and sometimes buck – the White House if he is to pursue an agenda of change.
  • A principal question for those involved in drug and device development will be how Gottlieb and the leadership team at the FDA, under increasingly limited financial and workforce resources, will respond to the desire by lawmakers, the Trump Administration and the public for new and faster medical advancements while keeping costs low.

A poet from West London once wrote, "Meet the new boss, same as the old boss," a frustrated statement lamenting that the status quo in any system tends to prevail despite calls for revolution. If one judges the potential for change at the U.S. Food and Drug Administration (FDA) based on its highest leadership, Dr. Scott Gottlieb's confirmation on May 9, 2017, as Commissioner of Food and Drugs marks an opportunity for Congress and the public to determine whether he will be able to break the status quo or merely uphold it.

Gottlieb's Background the New Normal?

In terms of experience, Gottlieb would appear to be a status quo choice. Gottlieb is a board certified physician in internal medicine and has significant past experience in the federal government, most notably serving as FDA Deputy Commissioner for Medical and Scientific Affairs. His time working with the FDA, the Centers for Medicare & Medicaid Services (CMS), and other federal agencies has given him extensive experience with a diverse set of healthcare issues, including global health, health IT and biodefense. It was similar government service that made former President Barack Obama's first choice for the FDA lead, Dr. Margaret Hamburg – also an internal medicine physician – a natural one. She was confirmed unanimously by the U.S. Senate in 2009.

In addition, Gottlieb has spent several years consulting for numerous organizations in the biotech industry and has served on the boards of a handful of such companies, including Gradalis and Tolero Pharmaceuticals. He has also served as a partner at New Enterprise Associates, a venture capital firm that has advised or invested in dozens of healthcare entities and biotech companies, including GlaxoSmithKline and Vertex Pharmaceuticals. Although traditionally a source of concern among lawmakers, Gottlieb's involvement with industry may now be considered closer to the norm as Gottlieb's immediate predecessor, Duke University cardiologist Dr. Robert Califf was also involved with industry, gaining support from numerous entities to finance the clinical research center he founded at Duke. Both Hamburg and Califf have publicly endorsed Gottlieb for the post.

While Gottlieb's selection extends a nascent pattern of industry expertise in the agency's top office, what differentiates his confirmation are the political circumstances surrounding it. His confirmation hearing before the Senate Health, Education, Labor and Pensions (HELP) Committee and subsequent vote, which represent the first two hurdles to confirmation as FDA chief, were on the whole uneventful, especially given his self-imposed, year-long moratorium on personal involvement in agency decisions with respect to more than 20 companies to which he's had financial or advisory ties. However, it was plain to those watching, and those who have followed actions by the Trump Administration in recent months, that Gottlieb and his staff will have to be mindful of several issues in the near-term. Two of those – funding and politics – will affect operations, staffing and other resources at the agency, and potentially put the agency chief in the position of having to educate – and sometimes buck – the White House if he is to pursue an agenda of change at the FDA.

Funding a Key Challenge

To get a sense of how difficult it is to generate consistent non-defense discretionary funding for agencies like the FDA, one need look only at the National Institutes of Health (NIH). Over the past two decades, the NIH has garnered strong bipartisan support in Congress and throughout multiple presidential administrations, leading to calls for increased funding and resources for the agency to fulfill its research and public health agenda. Despite such popularity, following its doubling in funding from $13.6 billion to $27.1 billion in the early 2000s, the NIH has seen only modest increases in its overall budget, which now stands at approximately $34 billion. And, even with baseline funding increases, purchasing power at the NIH has dropped by more than 20 percent since 2003, as discretionary funding has been unable to keep pace with biomedical research inflation.

The game is even tougher for the FDA, as funding for the agency tends to take a backseat in Congress and, to a certain extent, with the public. This is because, in part, FDA funding is split between discretionary funding and user fees, which are carefully negotiated between industry and the agency to fund the review of new products and other activities. However, these fees, which made up 42 percent of FDA's overall funding in Fiscal Year (FY) 2016, are very limited in scope, leaving less than $3 billion of discretionary funding to run the remaining operations of an agency that has nearly 17,000 employees and whose regulated industries account for more than a quarter of total U.S. consumer spending.

The 21st Century Cures Act, which was signed into law at the end of last Congress, promised to deliver new provisions affecting or establishing policies and programs at the NIH, FDA, and the Health Resources and Services Administration (HRSA), among other agencies, as well as a much needed funding boost for these agencies to implement the law. Indeed, the legislation included $4.8 billion over 10 years for the NIH outside of the regular appropriations process for major projects, including the Precision Medicine Initiative and the BRAIN Initiative. However, while this funding increase served as a strong congressional endorsement of the NIH's mission, little can be made of the mere $500 million over 10 years granted by the bill to the FDA. This small sum must supplement numerous provisions in the law to accelerate and expand the FDA's review work, including advancing therapies for rare diseases, expanding the patient voice in drug development and accelerating approval pathways for regenerative medicine therapies, among many others. This same sentiment was echoed in the recently passed FY 2017 appropriations bill, in which the NIH saw an increase of $2 billion to the FDA's $39 million. In sum, Gottlieb and team must do more with less – and not in a political vacuum.

A Look Ahead

Many recent discussions have focused on both accelerating FDA drug and device reviews to get patients new therapies as quickly as possible and escalating drug prices, especially following recent investigations into the pricing practices of several pharmaceutical companies. As many remember, President Donald Trump was critical of the FDA's drug approval process in his February speech to a joint session of Congress, calling the process "slow and burdensome" and saying that it prevented therapies from getting to the patients who need them. While the speech, held on Rare Disease Day, did elevate an important message about the development of therapies for the rare disease population, median approval times for both new drug applications and biologics license applications have actually quickened over the past five years, from 10.8 months to 10.1, a vast improvement over the 26.9 months it took in 1993. This same trend also applies to medical devices, which now take about eight months for approval rather than more than a year in 2010. Compared with the European Medicines Agency (EMA), the FDA's review times are about two months faster despite approving 26 more products than the EMA during the same time period.

Regardless of those improvements, the Trump Administration has committed itself, and especially FDA leadership, to be even more efficient and effective by "doubling" the total amount of industry funding collected from the aforementioned user fees to more than $2 billion in the administration's FY 2018 budget blueprint, presumably to give more resources to FDA's review divisions. However, the FDA currently takes in just shy of $1.4 billion annualized in user fees in FY 2017 – assuming that "medical products" include prescriptions, generics, biosimilars and medical devices – and the FY 2018 user fee amounts have already been negotiated between the FDA and industry. Given that the FY 2018 base fee amounts already grant at least $430 million over FY 2017, excluding workload and inflation adjustments, the administration's proposal could strain industry relationships by calling for a renegotiation to the user fee amounts while yielding very little for the agency in terms of added financial resources. Thus, while a call for increased FDA funding could be a deeper signal of confidence in Gottlieb's ability to create a balance between the administration and industry, he will certainly be preoccupied with running an agency that currently has more than 1,000 job vacancies and is still subject to an administration-ordered hiring freeze that, unless completely lifted, will continue to affect the FDA's ability to hire senior-level experts.

As for drug prices, President Trump had made their reduction a notable campaign promise. Since taking office, he has found basic alignment on the issue with several unlikely individuals in Congress on the opposite end of the political spectrum, including Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.). Although there have been conversations between drug pricing hawks on both sides of the aisle, no precise agreements have been arranged. Gottlieb has already toed the line in his confirmation hearing by supporting unspecified mechanisms to increase competition in the pharmaceutical market to drive down costs. However, the FDA remains a public health agency that is statutorily limited to reviewing and approving new therapies, not negotiating and setting their prices. And although Gottlieb's views on the issue could create a new environment for conversations between the agency and industry concerning drug prices, any changes will most likely happen over the long term through larger changes in healthcare reimbursements.

A principal question for those involved in drug and device development will be how Gottlieb and the leadership team at the FDA, under increasingly limited financial and workforce resources, will respond to the desire by lawmakers, the administration and the public for new and faster medical advancements while keeping costs low. At this point, one can only begin to speculate at the progress of innovation during Gottlieb's tenure. However, it seems likely that change will be slower – and the status quo more persistent – than many predicted at the beginning of the 45th presidency.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.